Close Menu

Ambry

Many companies and counselors see the COVID-19 pandemic as a catalyst for moving germline risk testing into a digital-first healthcare model.

The company believes results from a new study help demonstrate the clinical value of its targeted RNA-seq method, an add-on to its DNA hereditary cancer tests.

The company's +RNAinsight test, a combined DNA and RNA genetic test for hereditary cancer syndromes, was launched in October.

The firms are combining Caris' somatic and Ambry's germline testing to provide clinicians with information on patients' cancers.

The firm hopes to return fewer VUS in its test reports and to accelerate the resolution of uncertain results issued to patients in that past.

The team analyzed multigene panel test data from Ambry Genetics for 165,000 individuals, focusing on hereditary cancer risk related to 32 genes in six cancer types.

My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.

The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.

A brief recap of Diagnostics news the week of Feb 1, 2019: Ambry Genetics, Quotient, Angle, PathAI, C2N Diagnostics, Interpace Diagnostics

CMS's move to restrict coverage could limit test access for early-stage cancer patients and negatively impact lab revenues.

Pages